Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus TZ 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus TZ 3.
SPRX-105 vs TZ-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
SPRX-105 is administered orally at a dose of 50 mg once daily.
100 mg orally twice daily
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Category C
Category C
Unknown
Unknown